PMID- 19083077
OWN - NLM
STAT- MEDLINE
DCOM- 20090814
LR  - 20220321
IS  - 1439-7595 (Print)
IS  - 1439-7595 (Linking)
VI  - 19
IP  - 2
DP  - 2009
TI  - Improvement of the HAQ score by infliximab treatment in patients with RA: its 
      association with disease activity and joint destruction.
PG  - 166-72
LID - 10.1007/s10165-008-0142-0 [doi]
AB  - We conducted a two-year prospective study to clarify the efficacy of infliximab 
      at improving the health assessment questionnaire (HAQ) score and associated 
      factors in 67 patients with advanced rheumatoid arthritis (RA). All patients were 
      scheduled to receive infliximab at a dose of 3 mg/kg at weeks 0, 2, 6 and every 
      eight weeks thereafter through to week 102, and were fully examined at the time 
      of each infusion. Parameters of disease activity such as the serum level of 
      C-reactive protein (CRP), the serum level of matrix metalloproteinase-3 (MMP-3) 
      and the 28-joint disease activity score (DAS28) were obtained, and the functional 
      capabilities of the patients were assessed using the HAQ score. The serum CRP, 
      the MMP-3, the DAS28(CRP) level, and the mean HAQ score decreased rapidly at two 
      weeks after the start of infliximab treatment (CRP from 3.7 to 0.9 mg/dl, MMP-3 
      from 362.3 to 192.8 ng/ml, DAS28(CRP) from 5.6 to 3.7, and HAQ score from 1.5 to 
      0.9). Compared with the baseline values, the mean progression of the modified van 
      der Heijde (vdH)-Sharp score after one year was 4.4 +/- 5.8 (median: 3.0), and 
      that after two years was 3.1 +/- 6.9 (median: 1.0). A 93% reduction in the rate 
      of joint destruction, as measured using the vdH-Sharp score, was estimated after 
      infliximab therapy. Patients with less joint damage (shorter disease duration or 
      lower vdH-Sharp score) regained more of their daily activities. The present study 
      demonstrated the importance of activity control before the progression of 
      irreversible factors, such as joint destruction, for maintaining the functional 
      capacities of RA patients.
FAU - Nagasawa, Hayato
AU  - Nagasawa H
AD  - Department of Rheumatology, Saitama Medical Center, Saitama Medical University, 
      1981 Tsujido-machi, Kamoda, Kawagoe 350-8550, Japan. nagasawa@saitama-med.ac.jp
FAU - Kameda, Hideto
AU  - Kameda H
FAU - Sekiguchi, Naoya
AU  - Sekiguchi N
FAU - Amano, Kouichi
AU  - Amano K
FAU - Takeuchi, Tsutomu
AU  - Takeuchi T
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20081213
PL  - England
TA  - Mod Rheumatol
JT  - Modern rheumatology
JID - 100959226
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antibodies, Monoclonal)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Arthritis, Rheumatoid/diagnosis/diagnostic imaging/*drug therapy
MH  - Arthrography
MH  - Disease Progression
MH  - Female
MH  - Health Surveys
MH  - Humans
MH  - Infliximab
MH  - Kinetics
MH  - Male
MH  - Middle Aged
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2008/12/17 09:00
MHDA- 2009/08/15 09:00
CRDT- 2008/12/17 09:00
PHST- 2008/08/12 00:00 [received]
PHST- 2008/11/04 00:00 [accepted]
PHST- 2008/12/17 09:00 [entrez]
PHST- 2008/12/17 09:00 [pubmed]
PHST- 2009/08/15 09:00 [medline]
AID - 10.1007/s10165-008-0142-0 [doi]
PST - ppublish
SO  - Mod Rheumatol. 2009;19(2):166-72. doi: 10.1007/s10165-008-0142-0. Epub 2008 Dec 
      13.